AI Analysis
AI-generated analysis. Always verify with the original filing.
CytoSorbents Corporation received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing.
Key Takeaways
1Received Extension Notice on April 1, 2026, granting 180-day period until September 28, 2026, per Nasdaq Rule 5810(c)(3)(A).
2Compliance requires Common Stock bid price to close at $1.00 or more for 10 consecutive trading days.
3No immediate effect on Nasdaq listing or SEC reporting obligations.
4Previously non-compliant since October 2, 2025, with initial 180-day period ending March 31, 2026.
5Plans to monitor bid price and consider options like reverse stock split.
6No assurance of regaining compliance or avoiding delisting.